substance p has been researched along with Neoplasms in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (13.04) | 18.7374 |
| 1990's | 1 (2.17) | 18.2507 |
| 2000's | 15 (32.61) | 29.6817 |
| 2010's | 18 (39.13) | 24.3611 |
| 2020's | 6 (13.04) | 2.80 |
| Authors | Studies |
|---|---|
| Li, Z; Liu, L; Mu, L; Song, J; Wang, K; Wang, R; Xing, Y; Zhang, B; Zhang, W | 1 |
| Esteban, F; González-Moles, MÁ; Muñoz, M; Ramos-García, P | 1 |
| Coveñas, R; Muñoz, M; Robinson, P | 1 |
| Amit, M; Xie, T; Ye, Y | 1 |
| Coveñas, R; Muñoz, M; Robinson, P; Rodríguez, FD | 1 |
| Ding, G; Jia, L; Jiang, F; Li, J; Ouyang, X; Sun, Y; Wang, L; Wang, Y; Yang, C; Yu, R; Zhu, Z | 1 |
| An, HJ; Cho, SS; Kim, HH; Ko, YH; Park, HS; Shim, BY; Sun, S; Won, HS | 1 |
| Hashemy, SI; Javid, H; Mohammadi, F; Zahiri, E | 1 |
| Coveñas, R; Muñoz, M | 5 |
| Jia, MM; Li, XJ; Li, YS; Mao, XQ; Tang, HB; Yang, YL | 1 |
| Cassinello, F; del Olmo, M; Prieto, I; Rivas, S; Strichartz, GR | 1 |
| Covenas, R; Esteban, F; Munoz, M; Redondo, M | 1 |
| Bosnjak, SM; Dimitrijevic, J; Djordjevic, F | 1 |
| Hiller, JG; Ho, KM; Kuruvilla, N; Millen, R; Ramsay, R; Riedel, B; Sampurno, S | 1 |
| Grunberg, S; Hawkins, R | 1 |
| Barbosa, AL; Moraes, MO; Oliveira, GJ; Pinheiro, CA; Ribeiro, RA; Souza, MH; Vale, ML | 1 |
| Darmani, NA; Ray, AP | 1 |
| Brawley, CM; Kossiakoff, AA; Luchniak, A; Rizk, SS; Rock, RS; Uysal, S | 1 |
| Ahn, KS; Kim, KH; Kim, SH; Lee, CH; Lee, EO; Lee, HJ; Lee, JH; Lee, KS; Nam, DW | 1 |
| Coveñas, R; Muñoz, M; Rosso, M | 2 |
| Almendro, V; Ametller, E; Casas, I; Fernández-Nogueira, P; García-Recio, S; Gascón, P; Mayordomo, C; Pastor-Arroyo, EM; Vinyals, L | 1 |
| Auber, ML; Higa, GM; Hobbs, G | 1 |
| Berger, M; Muñoz, M; Rosso, M | 1 |
| Coveñas, R; Martinez-Armesto, J; Muñoz, M | 1 |
| Aapro, M; Carides, AD; Evans, JK; Hargreaves, R; Hesketh, PJ; Horgan, KJ; Naylor, RJ; Tattersall, FD; Van Belle, S | 1 |
| GRABNER, K; LEMBECK, F | 1 |
| Duffy, RA | 1 |
| Krenning, EP; Mäcke, HR; Reubi, JC | 1 |
| Ohtori, S; Shimoyama, M; Shimoyama, N; Tanaka, K; Tatsuoka, H | 1 |
| Clemente, C; Leo, S; Riezzo, G; Russo, F | 1 |
| Esteban, F; González-Moles, MA; Muñoz, M; Rosso, M | 1 |
| Kondraciuk, B; Miskowiak, B; Nowicki, M; Ostalska-Nowicka, D | 1 |
| Ding, M; Hald, A; Hansen, RR; Heegaard, AM; Nedergaard, S | 1 |
| Wilkin, JK | 1 |
| Neumayr, A | 1 |
| Achem-Karam, S; Owyang, C; Vinik, AI | 1 |
| Conlon, JM; Lahuerta, J; Lipton, S; Miles, J | 1 |
| Bleiberg, H | 1 |
| Byrne, B; Clive, S; Jodrell, DI; MacLellan, A; Robson, L; Smyth, JF; Webb, DJ; Young, A | 1 |
| Cannon, D; Cusack, D; Powell, D; Skrabanek, P | 1 |
| Lamers, CB; Van Tol, EA; Verspaget, HW | 1 |
26 review(s) available for substance p and Neoplasms
| Article | Year |
|---|---|
Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature.
Topics: Cell Proliferation; Humans; Inflammation; Neoplasms; Receptors, Neurokinin-1; Substance P | 2021 |
Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Chemoradiotherapy; Drug Repositioning; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Substance P | 2023 |
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant.
Topics: Antineoplastic Agents; Aprepitant; Drug Repositioning; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Quality of Life; Receptors, Neurokinin-1; Substance P | 2023 |
The emerging role of substance P/neurokinin-1 receptor signaling pathways in growth and development of tumor cells.
Topics: Animals; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Humans; Neoplasms; Receptors, Neurokinin-1; Signal Transduction; Substance P | 2019 |
Involvement of substance P and the NK-1 receptor in cancer progression.
Topics: Apoptosis; Cell Proliferation; Cell Survival; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Protein Precursors; Receptors, Neurokinin-1; RNA, Messenger; Substance P; Tachykinins | 2013 |
Cancer progression and substance P.
Topics: Animals; Disease Progression; Humans; Neoplasm Invasiveness; Neoplasms; Neovascularization, Pathologic; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P | 2014 |
Involvement of substance P and the NK-1 receptor in human pathology.
Topics: Alcoholism; Animals; Bacterial Infections; Depression; Humans; Inflammation; Migraine Disorders; Neoplasms; Pain; Receptors, Neurokinin-1; Seizures; Stress, Psychological; Substance P; Virus Diseases; Vomiting | 2014 |
Cancer surgery: how may anesthesia influence outcome?
Topics: Anesthesia; Anesthetics, Local; Apoptosis; Cell Movement; Cell Proliferation; Disease Progression; Humans; Neoplasms; Substance P; Voltage-Gated Sodium Channels | 2015 |
The substance P/NK-1 receptor system: NK-1 receptor antagonists as anti-cancer drugs.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Aprepitant; Cell Movement; Cell Proliferation; Emotions; Humans; Inflammation; Morpholines; Neoplasms; Neovascularization, Pathologic; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P | 2015 |
Cancer and chemotherapy-induced nausea and vomiting: a focus on olanzapine.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Humans; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Substance P; Vomiting | 2016 |
Chemotherapy-induced nausea and vomiting: challenges and opportunities for improved patient outcomes.
Topics: Antiemetics; Antineoplastic Agents; Humans; Metoclopramide; Nausea; Neoplasms; Substance P; Treatment Outcome; Vomiting | 2009 |
Evidence for a re-evaluation of the neurochemical and anatomical bases of chemotherapy-induced vomiting.
Topics: Antineoplastic Agents; Cannabinoids; Dopamine; Eicosanoids; Gastrointestinal Tract; Humans; Neoplasms; Nervous System; Serotonin; Substance P; Vomiting | 2009 |
A new frontier in the treatment of cancer: NK-1 receptor antagonists.
Topics: Antineoplastic Agents; Humans; Neoplasms; Neovascularization, Pathologic; Neurokinin-1 Receptor Antagonists; Peptides; Receptors, Neurokinin-1; Substance P | 2010 |
Neurokinin-1 receptor: a new promising target in the treatment of cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Humans; Molecular Targeted Therapy; Neoplasms; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P | 2010 |
The NK-1 receptor: a new target in cancer therapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Drug Delivery Systems; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Protein Binding; Receptors, Neurokinin-1; Substance P | 2011 |
NK-1 receptor antagonists: a new generation of anticancer drugs.
Topics: Animals; Antineoplastic Agents; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Receptors, Neurokinin-1; Substance P | 2012 |
The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer.
Topics: Emotions; Humans; Immunohistochemistry; Inflammation; Neoplasms; Receptors, Neurokinin-1; Substance P; Tumor Microenvironment | 2012 |
NK-1 receptor antagonists as antitumor drugs: a survey of the literature from 2000 to 2011.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Dose-Response Relationship, Drug; Drug Delivery Systems; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Patents as Topic; Substance P | 2012 |
Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Clinical Trials, Phase II as Topic; Drug Therapy, Combination; Granisetron; Humans; Morpholines; Neoplasms; Neurokinin-1 Receptor Antagonists; Neurotransmitter Agents; Ondansetron; Prodrugs; Serotonin; Serotonin Antagonists; Substance P; Vomiting | 2003 |
Potential therapeutic targets for neurokinin-1 receptor antagonists.
Topics: Analgesics; Anti-Anxiety Agents; Anti-Asthmatic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antiemetics; Antineoplastic Agents; Antitussive Agents; Anxiety; Asthma; Clinical Trials as Topic; Cough; Cystitis; Depression; Drug Design; Humans; Inflammation; Irritable Bowel Syndrome; Neoplasms; Neurokinin-1 Receptor Antagonists; Pain; Substance P; Vomiting | 2004 |
Candidates for peptide receptor radiotherapy today and in the future.
Topics: Animals; Biomarkers, Tumor; Bombesin; Cholecystokinin; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Humans; Neoplasms; Peptides; Practice Guidelines as Topic; Practice Patterns, Physicians'; Radioisotopes; Radiopharmaceuticals; Receptors, Peptide; Somatostatin; Substance P; Treatment Outcome | 2005 |
A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Disease Progression; DNA Damage; Growth Substances; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Oncogenes; Receptors, Neurokinin-1; Signal Transduction; Substance P; Tachykinins | 2006 |
The significance of substance P in physiological and malignant haematopoiesis.
Topics: Antineoplastic Agents; Bone Marrow; Cell Transformation, Neoplastic; Hematopoiesis; Humans; Leukemia; Neoplasm Metastasis; Neoplasm Proteins; Neoplasms; Substance P; Tachykinins | 2007 |
Flushing reactions: consequences and mechanisms.
Topics: Chlorpropamide; Disulfiram; Drug Interactions; Endorphins; Ethanol; Female; Glutamates; Hot Temperature; Humans; Malignant Carcinoid Syndrome; Menopause; Neoplasms; Skin; Skin Physiological Phenomena; Substance P; Vasomotor System | 1981 |
Gastrointestinal hormones in clinical medicine.
Topics: Chemical Phenomena; Chemistry; Cholecystokinin; Diabetes Mellitus; Diarrhea; Endocrine System Diseases; Gastric Inhibitory Polypeptide; Gastrins; Gastrointestinal Hormones; Glucagon; Humans; Hypoglycemia; Motilin; Neoplasms; Neurotensin; Pancreatic Polypeptide; Peptic Ulcer; Secretin; Skin Diseases; Somatostatin; Substance P; Vasoactive Intestinal Peptide | 1982 |
A new class of antiemetics: the NK-1 receptor antagonists.
Topics: Animals; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Humans; Neoplasms; Neurokinin-1 Receptor Antagonists; Substance P; Vomiting | 2000 |
2 trial(s) available for substance p and Neoplasms
| Article | Year |
|---|---|
Impact of celecoxib on inflammation during cancer surgery: a randomized clinical trial.
Topics: Aged; Celecoxib; Cyclooxygenase 2 Inhibitors; Female; Follow-Up Studies; Humans; Inflammation; Male; Middle Aged; Neoplasms; Pain, Postoperative; Prospective Studies; Substance P | 2017 |
Forearm blood flow and local responses to peptide vasodilators: a novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist.
Topics: Adult; Aged; Antineoplastic Agents; Brachial Artery; Bradykinin; Dose-Response Relationship, Drug; Female; Flushing; Forearm; Humans; Infusion Pumps; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neuropeptides; Oligopeptides; Regional Blood Flow; Substance P; Treatment Outcome; Vasodilator Agents | 2001 |
18 other study(ies) available for substance p and Neoplasms
| Article | Year |
|---|---|
Improving anticancer activity and selectivity of camptothecin through conjugation with releasable substance P.
Topics: Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Cell Survival; Delayed-Action Preparations; Drug Delivery Systems; Humans; Molecular Structure; Neoplasms; Neurotransmitter Agents; Substance P | 2011 |
Targeting the Nerve-Cancer Circuit.
Topics: Humans; Neoplasms; Neurons; Neuropeptides; Receptors, Neurokinin-1; Substance P | 2023 |
Pain May Promote Tumor Progression via Substance P-Dependent Modulation of Toll-like Receptor-4.
Topics: Humans; Neoplasms; Pain; Receptors, Neurokinin-1; Substance P; Toll-Like Receptor 4 | 2020 |
Elevated serum substance P level as a predictive marker for moderately emetogenic chemotherapy-induced nausea and vomiting: A prospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Emetics; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neoplasms; Prognosis; Prospective Studies; Substance P; Survival Rate; Vomiting | 2021 |
Involvement of substance p/neurokinin-1 receptor in the analgesic and anticancer activities of minimally toxic fraction from the traditional Chinese medicine Liu-Shen-Wan in vitro.
Topics: Analgesics; Antineoplastic Agents; Apoptosis; Bradykinin; Complex Mixtures; Dose-Response Relationship, Drug; Down-Regulation; Ganglia, Spinal; Hep G2 Cells; Hepatoblastoma; Humans; Liver Neoplasms; Medicine, Chinese Traditional; Mitochondria; Neoplasms; Pain; Phytotherapy; Receptors, Neurokinin-1; Substance P | 2014 |
Tumor bearing decreases systemic acute inflammation in rats--role of mast cell degranulation.
Topics: Animals; Bradykinin; Capillary Permeability; Capsaicin; Carrageenan; Cell Degranulation; Dextrans; Edema; Histamine; Inflammation; Mast Cells; Neoplasm Transplantation; Neoplasms; Neutrophil Activation; Neutrophil Infiltration; p-Methoxy-N-methylphenethylamine; Rats; Rats, Wistar; Serotonin; Substance P | 2009 |
An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells.
Topics: Actins; Amino Acid Sequence; Cell Line, Tumor; Cell Survival; Drug Delivery Systems; Endocytosis; Humans; Immunoglobulin Fragments; Molecular Sequence Data; Mutant Proteins; Neoplasms; Protein Binding; Protein Engineering; Receptors, Neurokinin-1; Substance P | 2009 |
Substance P and beta endorphin mediate electroacupuncture induced analgesic activity in mouse cancer pain model.
Topics: Acupuncture Analgesia; Acupuncture Points; Animals; beta-Endorphin; Cell Line, Tumor; Disease Models, Animal; Electroacupuncture; Humans; Male; Mice; Mice, Inbred BALB C; Neoplasms; Pain; Pain Management; Pain Threshold; Substance P | 2009 |
Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.
Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Ligands; Male; Neoplasms; Neurokinin-1 Receptor Antagonists; Piperidines; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Neurokinin-1; Signal Transduction; Substance P; Trastuzumab | 2012 |
Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Biomarkers; Case-Control Studies; Creatinine; Dexamethasone; Drug Therapy, Combination; Female; Humans; Hydroxyindoleacetic Acid; Male; Middle Aged; Neoplasms; Predictive Value of Tests; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Substance P; Time Factors; Vomiting | 2012 |
[Studies on the content of substance P and serotonin in brain tumors].
Topics: Brain Chemistry; Brain Neoplasms; Neoplasms; Serotonin; Substance P | 1960 |
Change of dorsal horn neurochemistry in a mouse model of neuropathic cancer pain.
Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Male; Mice; Mice, Inbred BALB C; Neoplasms; Pain; Peripheral Nervous System Diseases; Posterior Horn Cells; Substance P | 2005 |
The role of electrogastrography and gastrointestinal hormones in chemotherapy-related dyspeptic symptoms.
Topics: Aged; Antineoplastic Agents; Dyspepsia; Electrophysiology; Female; Gastrins; Gastrointestinal Hormones; Gastrointestinal Motility; Humans; Male; Neoplasms; Serotonin; Stomach; Substance P; Vasopressins | 2005 |
Differential activation of spinal cord glial cells in murine models of neuropathic and cancer pain.
Topics: Animals; Behavior, Animal; Bone Neoplasms; Cell Line; Glial Fibrillary Acidic Protein; Gliosis; Immunohistochemistry; Mice; Mice, Inbred C3H; Neoplasms; Neuroglia; Pain; Pain Measurement; Peripheral Nervous System Diseases; Peripheral Nervous System Neoplasms; Physical Stimulation; Spinal Cord; Substance P; Tomography, X-Ray Computed | 2009 |
[The APUD concept and its clinical significance. 2. Effect of gastrointestinal hormones, polypeptides and neurotransmitters on the physiological course and disease processes of the intestinal tract and the nervous system].
Topics: APUD Cells; Cholecystokinin; Hormones; Humans; Intestinal Diseases; Neoplasms; Nervous System Diseases; Neurotensin; Neurotransmitter Agents; Peptides; Substance P | 1982 |
Changes in the concentration of somatostatin and substance P in the cerebrospinal fluid following injection of alcohol into the pituitary gland.
Topics: Ethanol; Female; Humans; Male; Neoplasms; Pain, Intractable; Pituitary Gland, Posterior; Radioimmunoassay; Somatostatin; Substance P | 1984 |
Substance P plasma levels in pregnancy and in various clinical disorders.
Topics: Cystic Fibrosis; Female; Humans; Intestinal Diseases; Neoplasms; Pregnancy; Radioimmunoassay; Substance P; Thyroid Diseases | 1979 |
Neuropeptide regulation of cell-mediated cytotoxicity against human tumor cells.
Topics: Bombesin; Cytotoxicity Tests, Immunologic; Cytotoxicity, Immunologic; Humans; Monocytes; Neoplasms; Neuropeptides; Neurotensin; Somatostatin; Substance P; Tumor Cells, Cultured | 1990 |